(Q37234179)

19 August 2017

0 references

Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1 reference

1 reference

1 reference

Eui Bae Kim

1

1 reference

19 August 2017

Dae Sik Kim

2

1 reference

19 August 2017

Seh Jong Park

3

1 reference

19 August 2017

Yong Park

4

1 reference

19 August 2017

Kyoung Ho Rho

5

1 reference

19 August 2017

Seok Jin Kim

6

1 reference

19 August 2017

31 March 2008

1 reference

Cancer Research and Treatment

19 August 2017

1 reference

19 August 2017

40

1 reference

19 August 2017

1

1 reference

19 August 2017

36-38

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

31 March 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Reactivation of hepatitis B virus with rituximab.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Occult hepatitis B virus infection and its clinical implications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Hepatitis B virus DNA contains a glucocorticoid-responsive element

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Occult hepatitis B virus infection: a hidden menace?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699087

3 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/19688064

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688064

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19688064

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4143/CRT.2008.40.1.36

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19688064

1 reference